U.S. market Closed. Opens in 11 hours 32 minutes

LVTX | LAVA Therapeutics N.V. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue6.77M19.39M5.00M3.92MN/A
Cost of Revenue3.48MN/AN/A12.85M7.44M
Gross Profit3.29M19.39M5.00M-8.93M-7.44M
Operating Expenses46.54M54.23M49.35M19.66M9.58M
Selling, General & Admin12.73M14.12M12.16M2.88M1.24M
Research & Development33.81M40.10M37.19M16.78M8.35M
Other Operating ExpensesN/A3.18MN/A0N/A
Operating Income-43.25M-34.84M-44.35M-15.74M-9.58M
Other Expenses / Income-1.41M3.18M-837.00K-924.92K-104.00K
Before Tax Income-41.70M-31.66M-45.19M-16.66M-9.69M
Income Tax Expenses279.00K249.00K157.00K43.05K86.00K
Net Income-41.97M-31.91M-45.35M-16.71M-9.77M
Interest Expenses232.00K82.00K625.00K361.61K86.00K
Basic Shares Outstanding26.73M25.92M19.76M25.35M18.41M
Diluted Shares Outstanding26.73M25.92M19.76M25.35M18.41M
EBITDA-38.77M-33.72M-44.35M-15.25M-9.32M
EBITDA Margin-572.80%-173.88%-887.06%-389.05%0.00%
EBIT-41.46M-31.58M-44.56M-16.30M-9.60M
EBIT Margin-612.54%-162.84%-891.30%-416.04%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙